Article By:
Scott Matusow
Thursday, March 21, 2024 2:25 AM EDT
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund
What does this mean for $GLYC?